2,436
Views
3
CrossRef citations to date
0
Altmetric
Articles

The current treatment landscape in adult atopic dermatitis in the United States: results from a cross-sectional real-world study

, ORCID Icon, , , &
Pages 1707-1717 | Received 12 Feb 2021, Accepted 26 Feb 2021, Published online: 23 Mar 2021

References

  • Bieber T. Atopic dermatitis. Ann Dermatol. 2010;22(2):125–137.
  • Al-Naqeeb J, Danner S, Fagnan LJ, et al. The burden of childhood atopic dermatitis in the primary care setting: a report from the Meta-LARC consortium. J Am Board Fam Med. 2019;32(2):191–200.
  • Silverberg, JI. Atopic dermatitis in adults. Med Clin 2020;104(1):157–176
  • Boguniewicz M, Fonacier L, Guttman-Yassky E, et al. Atopic dermatitis yardstick: practical recommendations for an evolving therapeutic landscape. Ann Allergy Asthma Immunol. 2018;120(1):10–22.e2.
  • Dhadwal G, Albrecht L, Gniadecki R, et al. Approach to the assessment and management of adult patients with atopic dermatitis: a consensus document. Section IV: treatment options for the management of atopic dermatitis. J Cutan Med Surg. 2018; 22(1_suppl):21S–29S.
  • Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis. Section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116–132.
  • Yang H, Wang J, Shang X, et al. Application of topical phosphodiesterase 4 inhibitors in mild to moderate atopic dermatitis – a systematic review and meta-analysis. JAMA Dermatol. 2019;155(5):585–593.
  • Sidbury R, Davis DM, Cohen DE, et al. Guidelines of care for the management of atopic dermatitis. Section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014;71(2): 327–349.
  • Frampton JE and Blair HA. Duplimumab: a review in moderate-to-severe atopic dermatitis. Am J Clin Dermatol. 2018;19:617–624.
  • Feldman SR, Cox LS, Strowd LC, et al. The challenge of managing atopic dermatitis in the United States. Am Health Drug Benefits. 2019;12(2):83–93.
  • Cohen DE. New and emerging therapies for atopic dermatitis. Presented at the 2019 American Academy of Dermatology Annual Meeting; 2019 March 1-5; Washington, DC.
  • Armstrong AW, Huang A, Wang L, et al. Real-world utilization patterns of systemic immunosuppressants among US adult patients with atopic dermatitis. PLoS One. 2019;14(1):e0210517.
  • Eichenfield LF, DiBonaventura M, Xenakis J, et al. Costs and treatment patterns among patients with atopic dermatitis using advanced therapies in the United States: analysis of a retrospective claims database. Dermatol Ther (Heidelb). 2020;10(4):791–806.
  • Gooderham MJ, Bissonnette R, Grewal P, et al. Approach to the assessment and management of adult patients with atopic dermatitis: a consenus document. Section II: tools for assessing the severity of atopic dermatitis. J Cutaneous Med Surg. 2018;22(1S):10S–16S.
  • Futamura M, Leshem YA, Thomas KS, et al. A systematic review of investigator global assessment (IGA) in atopic dermatitis (AD) trials: many options, no standards. J Am Acad Dermatol. 2015;74(2):288–294.